{"altmetric_id":14611884,"counts":{"readers":{"mendeley":62,"citeulike":0,"connotea":0},"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["medindia"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa63c3cf058f610008ec7","authors":["Clark GM"],"doi":"10.1016\/j.molonc.2007.12.001","endpage":"412","first_seen_on":"2016-12-09T12:08:11+00:00","issns":["1574-7891","15747891"],"issue":"4","journal":"Molecular Oncology","last_mentioned_on":1481284798,"links":["http:\/\/www.moloncol.org\/article\/S1574-7891(07)00102-0\/abstract"],"pmid":"19383314","pubdate":"2008-04-14T23:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Life Sciences","Biochemistry, Genetics and Molecular Biology"],"startpage":"406","subjects":["molecularbiology","neoplasms"],"title":"Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib","type":"article","volume":"1","mendeley_url":"http:\/\/www.mendeley.com\/research\/prognostic-factors-versus-predictive-factors-examples-clinical-trial-erlotinib"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":7866440,"mean":6.6628832942016,"rank":1089864,"this_scored_higher_than_pct":85,"this_scored_higher_than":6705810,"rank_type":"exact","sample_size":7866440,"percentile":85},"similar_age_3m":{"total_number_of_other_articles":251505,"mean":12.286836424072,"rank":52308,"this_scored_higher_than_pct":77,"this_scored_higher_than":195681,"rank_type":"exact","sample_size":251505,"percentile":77},"this_journal":{"total_number_of_other_articles":373,"mean":2.842747311828,"rank":26,"this_scored_higher_than_pct":92,"this_scored_higher_than":346,"rank_type":"exact","sample_size":373,"percentile":92},"similar_age_this_journal_3m":{"total_number_of_other_articles":9,"mean":1.70625,"rank":2,"this_scored_higher_than_pct":77,"this_scored_higher_than":7,"rank_type":"exact","sample_size":9,"percentile":77}}},"demographics":{"users":{"mendeley":{"by_status":{"Professor > Associate Professor":5,"Student  > Doctoral Student":3,"Researcher":14,"Student  > Ph. D. Student":14,"Student  > Postgraduate":2,"Student  > Master":9,"Other":8,"Student  > Bachelor":3,"Lecturer":1,"Lecturer > Senior Lecturer":1,"Professor":2},"by_discipline":{"Medicine and Dentistry":29,"Neuroscience":1,"Chemistry":2,"Physics and Astronomy":2,"Immunology and Microbiology":2,"Economics, Econometrics and Finance":1,"Agricultural and Biological Sciences":12,"Computer Science":3,"Biochemistry, Genetics and Molecular Biology":4,"Mathematics":2,"Unspecified":3,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"mendeley":{"EC":2,"NL":1,"IE":1,"TW":1,"DK":1,"CL":1,"ES":1}}},"posts":{"news":[{"title":"HPV Antibodies Signal Better Prognosis for Head and Neck Cancer Patients","url":"http:\/\/ct.moreover.com\/?a=28873371760&p=1pl&v=1&x=ENDM9cCGwn45MXr3ZU-muQ","license":"public","citation_ids":[14611884,14568446],"posted_on":"2016-12-09T11:59:58+00:00","summary":"Highlights This is one of the first studies to show that HPV antibodies are a good prognostic marker for increased patient survival with head and neck cancer.","author":{"name":"Medindia","url":"http:\/\/www.medindia.net\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/864\/normal\/Screen_Shot_2016-02-02_at_16.39.45.png?1454431195"}}]}}